Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

Oncimmune Ltd.

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally. Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK has a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L. *

 

Period Start 2002-01-01 splitoff
  Group Freenome (Group)
  Predecessor University of Nottingham
Products Industry EarlyCDT® platform technology
  Industry 2 EarlyCDT®-Lung test (CLIA test)
     
Region Region Nottingham, Nottinghamshire
  Country United Kingdom (GB)
  Street 1 Thane Road
MediCity Nottingham, D6 Building
  City NG90 6BH Nottingham
  Tel +44-1157-840-500
    Address record changed: 2023-06-27
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 1,345,000 (revenue (2014/15) 2015-05-31)
  Profit -2,013,000 (2015-05-31)
     
    * Document for »About Section«: Oncimmune Holdings plc. (3/19/19). "Press Release: Oncimmune Announces the Acquisition of Protagen Diagnostics AG, a Leader in Personalised Immuno-Profiling". Cambridge, MA.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for Freenome (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top